GSK Announces Discontinuation of Injectable Therapy for T2D

This article originally appeared here.
Share this content:
Clinicians treating patients with Tanzeum should explore alternative therapies well ahead of July 2018.
Clinicians treating patients with Tanzeum should explore alternative therapies well ahead of July 2018.

GlaxoSmithKine is alerting healthcare professionals that the Company has made the decision to discontinue the commercial availability of Tanzeum (albiglutide for injection; 30 mg and 50 mg). The Company states that this was not related to any safety concerns regarding the product, but rather due to limited prescribing of the drug.

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. It was approved by the Food and Drug Administration (FDA) in 2014. 

As availability of the drug is likely to be depleted by July 2018, the Company is suggesting that clinicians put a plan in place to transition patients currently on Tanzeum to an alternative therapy before this time. In addition, Tanzeum therapy should not be started in any new patients.

Reference

TANZEUM (albiglutide) discontinuation — Q&A. Philadelphia, PA: GlaxoSmithKline. https://www.tanzeum.com/pdfs/consumer-faq.pdf. Published July 26, 2017. Accessed August 31, 2017.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters